suPAR levels reliably predict mortality in patients with suspected AMI

Mon Apr 08 2019

New abstract published in Clinical Research in Cardiology;

“Predictive value of suPAR for mortality in patients with suspected myocardial infarction” by Sörensen NA et al.


“Our study demonstrates that suPAR levels reliably predict mortality in the very heterogeneous group of patients presenting with symptoms suggestive of myocardial infarction in the emergency department. It, therefore, represents a valuable biomarker for risk estimation in this high-risk population”

and furthermore that

“In our study, suPAR alone achieved prognostic power comparable to the GRACE Score, a highly validated tool for predicting 6-month outcome in patients with ACS and a guideline recommended score for indicating patients as low risk after MI has been ruled out. Although suPAR did not improve GRACE score-based risk stratification substantially, the fact that a score, consisting of eight major risk factors including high-sensitivity troponin I, did not perform significantly better than the information derived by a single biomarker is remarkable.”

pdfLink to abstract here


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates